Cooperative Agreement UG3CA311400
Award Date 7/3/26
Completion Date 6/30/29
Dollars Obligated $327K
Federal Agency
Federal Grant Program
Assistance Type
Cooperative Agreement
Place of Performance
College Station, TX 77843, USA
Similar Awards
- Federal Cooperative Agreement Summary The University of Kansas Medical Center Research Institute, Inc. received a Cooperative Agreement award of $325,454 from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393), effective July 7, 2026, through June 30, 2029. The award funds a high-throughput screening (HTS) initiative to identify natural compounds that inhibit BCL9-β-catenin binding interactions as a strategy for breast cancer prevention....
- Federal Cooperative Agreement Summary Auburn University received a $317,704 Cooperative Agreement award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393), effective July 9, 2026 through June 30, 2029. The award funds research to develop novel pan-RAS (Rat Sarcoma) inhibitors derived from natural products for colorectal cancer interception. The research integrates high-throughput screening (HTS) of the NCI natural product library with...
- Federal Cooperative Agreement Summary The National Cancer Institute (NCI) awarded a $330,923 Cooperative Agreement to the Regents of the University of Michigan for a three-year project (July 1, 2026 – June 30, 2029) under the Cancer Cause and Prevention Research program (CFDA 93.393). This UG3/UH3 structured award aims to identify and validate first-in-class natural product inhibitors targeting CLBQ, an upstream thioesterase essential for colibactin biosynthesis. Colibactin is a genotoxin...
- Federal Cooperative Agreement Award Summary The National Cancer Institute awarded $323,226 to the University of Michigan's Office of Research and Sponsored Projects under the Cancer Cause and Prevention Research program (CFDA 93.393) effective August 1, 2025, through July 31, 2028. This Cooperative Agreement funds research focused on developing natural products targeting interleukin-8 (IL-8) signaling to intercept the progression of Barrett's esophagus to esophageal adenocarcinoma (EAC), a...
- Federal Cooperative Agreement Summary The National Cancer Institute (NCI) awarded a Cooperative Agreement totaling $225,511 to H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. on March 16, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394). The agreement supports the development and validation of a plasma-based multimodal digital polymerase chain reaction (PCR) assay designed to detect androgen receptor (AR) somatic alterations in metastatic...
- Federal Cooperative Agreement Summary The University of Arizona received $462,092 from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) to conduct investigative research on novel immune checkpoint targets for topical immunoprevention of non-melanoma skin cancer (NMSC). The two-year cooperative agreement, effective August 1, 2025 through July 31, 2027, will deliver research services examining the role of stress-induced immune checkpoint...
- Federal Cooperative Agreement Summary The National Cancer Institute (NCI) awarded a Cooperative Agreement totaling $681,310 to The Trustees of Columbia University in the City of New York, Health Sciences Division, effective June 24, 2026, through May 31, 2031, under the Cancer Biology Research program (CFDA 93.396). This award supports fundamental research to uncover mechanisms promoting bone metastasis in prostate cancer, which represents a major cause of mortality in prostate cancer...
- Federal Cooperative Agreement Award Summary The National Cancer Institute (NCI) awarded a $525,013 Cooperative Agreement to The University of Texas MD Anderson Cancer Center, effective September 1, 2025 through August 31, 2030, under the Cancer Detection and Diagnosis Research Program (CFDA 93.394). This award funds translational research to validate blood-based biomarkers for lung cancer risk assessment among individuals with no smoking history. The project will evaluate the predictive...
- Federal Cooperative Agreement Summary The National Cancer Institute (NCI) awarded The Institute for Cancer Research a Cooperative Agreement totaling $263,670 under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to support clinical translation of a urine-based biomarker for detecting residual disease in radical cystectomy candidates. The award, effective May 1, 2026, through April 30, 2028, funds development and validation of the Noninvasive Test for Assessment of Cancerous...
- Federal Cooperative Agreement Summary The National Cancer Institute (NCI) awarded $1,794,440 through its Cancer Biology Research program (CFDA 93.396) to the University of Massachusetts Medical School on August 28, 2025, for a five-year cooperative agreement extending through July 31, 2030. The award funds fundamental research on transfer RNA (tRNA) modification reprogramming and translational remodeling in cancer, with specific focus on melanoma progression and metastasis. The project will...